PathGroup Expands SmartGenomics Offering to Include Profiling of Hematologic Malignancies

BRENTWOOD, Tenn. – PathGroup, one of the largest private providers of pathology services in the United States, today announced launch of the SmartGenomics™ Heme Profile, which provides genomic profiling and information for patients that have failed or been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas and myeloproliferative/myelodysplastic diseases. The newly launched offering is based on collaboration between PathGroup, GenoSpace and the IP & Science business of Thomson Reuters.

Read more here.